Medtronic bought Cardiocom for $200 million in cash in an M&A deals bid to get into the disease management business.
Cardiocom, the company that was acquired in the M&A deals, makes devices aimed at helping to manage chronic conditions like diabetes or heart disease.
Medtronic, the company that acquired Cardiocom in the M&A deals, said it expects the effect of the buyout to be neutral to fiscal 2014 earnings.
With the M&A deals acquisition of Cardiocom, Medtronic's portfolio of products and services will span the continuum of care for the management of heart failure, which affects an estimated 7.5 million people in the U.S. and is a significant burden to the healthcare system - representing 1.1 million hospital visits per year in the U.S. at a cost of $39 billion each year.
Report: Congestive Heart Failure Partnering
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity